Patients at risk of complications of staphylococcus aureus bloodstream infection

Clinical Infectious Diseases

Volumn 48, Issue SUPPL. 4, 2009, Pages

  Rio, Ana Del ^a   Cervera, Carlos ^a   Moreno, Asuncion ^a   Moreillon, Phillipe ^b   Miró, José M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CHLORHEXIDINE; COTRIMOXAZOLE; DAPTOMYCIN; DOXYCYCLINE; INH A21; OCTENIDINE; POLYCLONAL ANTIBODY; POVIDONE IODINE; PSEUDOMONIC ACID; RIFAMPICIN; STAPHYLOCOCCUS VACCINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC THERAPY; BACTERIAL ARTHRITIS; BACTERIAL COLONIZATION; BACTERIAL ENDOCARDITIS; CATHETER REMOVAL; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; DIABETIC PATIENT; FEVER; HEART DISEASE; HEART VALVE PROSTHESIS; HEMODIALYSIS; HUMAN; INFECTION PREVENTION; INFECTION RISK; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; NOSE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SKIN DEFECT; SPONDYLITIS; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; ARTICLE; BACTEREMIA; ENDOCARDITIS; HETEROZYGOTE; ISOLATION AND PURIFICATION; MICROBIOLOGY; NOSE CAVITY; RISK FACTOR;

BACTEREMIA; CARRIER STATE; ENDOCARDITIS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; NASAL CAVITY; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 65649103042     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/598187     Document Type: Conference Paper

References (96)

1. Eggimann P, Pittet D. Acute bacteraemia. In: Fink MP, Abraham E, Vincent J, Kochanek P, eds. Textbook of critical care. Philadelphia: Elsevier Saunders, 2005:1275-83.
2. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM.CDCdefinitions for nosocomial infections, 1988. Am J Infect Control 1988; 16:128-40.
3. Fluit AC, Jones ME, Schmitz FJ, Acar J, Gupta R, Verhoef J. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY Antimicrobial Surveillance Program, 1997 and 1998. Clin Infect Dis 2000; 30:454-60.
4. Luzzaro F, Vigano EF, Fossati D, et al. Prevalence and drug susceptibility of pathogens causing bloodstream infections in northern Italy: a twoyear study in 16 hospitals. Eur J Clin Microbiol Infect Dis 2002; 21:849-55.
5. Shorr AF, Tabak YP, Killian AD, Gupta V, Liu LZ, Kollef MH.Healthcareassociated bloodstream infection: a distinct entity? Insights from a large US database. Crit Care Med 2006; 34:2588-95.
6. Fowler VG Jr, Miro JM, Hoen B, et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 2005; 293:3012-21.
7. Troidle L, Eisen T, Pacelli L, Finkelstein F. Complications associated with the development of bacteremia with Staphylococcus aureus. Hemodial Int 2007; 11:72-5.
8. Fowler VG Jr, BoucherHW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653-65.
9. Fowler VG Jr, Sanders LL, Kong LK, et al. Infective endocarditis due to Staphylococcus aureus: 59 prospectively identified cases with follow-up. Clin Infect Dis 1999; 28:106-14.
10. Chu VH, Crosslin DR, Friedman JY, et al. Staphylococcus aureus bacteremia in patients with prosthetic devices: costs and outcomes. Am J Med 2005; 118:1416.
11. Ringberg H, Thoren A, Lilja B. Metastatic complications of Staphylococcus aureus septicemia: to seek is to find. Infection 2000; 28:132-6.
12. Libman H, Arbeit RD. Complications associated with Staphylococcus aureus bacteremia. Arch Intern Med 1984; 144:541-5.
13. Jensen AG, Wachmann CH, Espersen F, Scheibel J, Skinhoj P, Frimodt-Moller N. Treatment and outcome of Staphylococcus aureus bacteremia: a prospective study of 278 cases. Arch Intern Med 2002; 162:25-32.
14. Lautenschlager S, Herzog C, Zimmerli W. Course and outcome of bac teremia due to Staphylococcus aureus: evaluation of different clinical case definitions. Clin Infect Dis 1993; 16:567-73.
15. Ruotsalainen E, Sammalkorpi K, Laine J, et al. Clinical manifestations and outcome in Staphylococcus aureus endocarditis among injection drug users and nonaddicts: a prospective study of 74 patients. BMC Infect Dis 2006; 6:137.
16. Cabell CH, Jollis JG, Peterson GE, et al. Changing patient characteristics and the effect on mortality in endocarditis. Arch Intern Med 2002; 162: 90-4.
17. Nadji G, Remadi JP, Coviaux F, et al. Comparison of clinical and morphological characteristics of Staphylococcus aureus endocarditis with endocarditiscaused by other pathogens. Heart 2005; 91:932-7.
18. Gould IM. MRSA bacteraemia. Int J Antimicrob Agents 2007; 30(Suppl 1):S66-70.
19. Engemann JJ, Friedman JY, Reed SD, et al. Clinical outcomes and costs\ e to Staphylococcus aureus bacteremia among patients receiving longterm hemodialysis. Infect Control Hosp Epidemiol 2005; 26:534-9.
20. Lepelletier D, Ferreol S, Villers D, Richet H. Methicillin-resistant Staphylococcus aureus nosocomial infections in ICU: risk factors, morbidity and cost [in French]. Pathol Biol (Paris) 2004; 52:474-9.
21. Friedman ND, Kaye KS, Stout JE, et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002; 137:791-7.
22. Siegman-Igra Y, Fourer B, Orni-Wasserlauf R, et al. Reappraisal of community-acquired bacteremia: a proposal of a new classification for the spectrum of acquisition of bacteremia. Clin Infect Dis 2002; 34:1431-9.
23. Willcox PA, Rayner BL, Whitelaw DA. Community-acquired Staphylococcus aureus bacteraemia in patients who do not abuse intravenous drugs. QJM 1998; 91:41-7.
24. Kaech C, Elzi L, Sendi P, et al. Course and outcome of Staphylococcus aureus bacteraemia: a retrospective analysis of 308 episodes in a Swiss tertiary-care centre. Clin Microbiol Infect 2006; 12:345-52.
25. Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005; 352: 1436-44.
26. King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and softtissue infections. Ann Intern Med 2006; 144:309-17.
27. Boyle-Vavra S, Daum RS. Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton-Valentine leukocidin. Lab Invest 2007; 87:3-9.
28. Coombs GW, Pearson JC, O'Brien FG, Murray RJ, Grubb WB, Christiansen KJ. Methicillin-resistant Staphylococcus aureus clones, Western Australia. Emerg Infect Dis 2006; 12:241-7.
29. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355:666-74.
30. Liassine N, Auckenthaler R, Descombes MC, Bes M, Vandenesch F,
31. Etienne J. Community-acquired methicillin-resistant Staphylococcus aureus isolated in Switzerland contains the Panton-Valentine leukocidin or exfoliative toxin genes. J Clin Microbiol 2004; 42:825-8.
32. Larsen A, Stegger M, Goering R, Sorum M, Skov R. Emergence and dissemination of the methicillin resistant Staphylococcus aureus USA300 clone in Denmark (2000-2005). Euro Surveill 2007; 12:22-4.
33. Rybak MJ, LaPlante KL. Community-associated methicillin-resistant Staphylococcus aureus: a review. Pharmacotherapy 2005; 25:74-85.
34. Diep BA, Chambers HF, Graber CJ, et al. Emergence of multidrugresistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med 2008; 148:249-57.
35. Cuijpers ML, Vos FJ, Bleeker-Rovers CP, et al. Complicating infectious foci in patients with Staphylococcus aureus or Streptococcus species bacteraemia. Eur J Clin Microbiol Infect Dis 2007; 26:105-13.
36. Fowler VG Jr, Olsen MK, Corey GR, et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med 2003; 163: 2066-72.
37. Khatib R, Saeed S, Sharma M, Riederer K, Fakih MG, Johnson LB. Impact of initial antibiotic choice and delayed appropriate treatment on the outcome of Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2006; 25:181-5.
38. Miró JM, Anguera I, Cabell CH, et al. Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. Clin Infect Dis 2005; 41: 507-14.
39. Chang FY, MacDonald BB, Peacock JE Jr, et al. A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine(Baltimore) 2003; 82:322-32.
40. El-Ahdab F, Benjamin DK Jr, Wang A, et al. Risk of endocarditis among patients with prosthetic valves and Staphylococcus aureus bacteremia. Am J Med 2005; 118:225-9.
41. Hill EE, Vanderschueren S, Verhaegen J, et al. Risk factors for infective endocarditis and outcome of patients with Staphylococcus aureus bacteremia. Mayo Clin Proc 2007; 82:1165-9.
42. Liao CH, Chen SY, Chang SC, Hsueh PR, Hung CC, Chen YC. Characteristics of community-acquired and health care-associated Staphylococcus aureus bacteremia in patients treated at the emergency department of a teaching hospital. Diagn Microbiol Infect Dis 2005; 53:85-92.
43. Horstkotte D, Follath F, Gutschik E, et al. Guidelines on prevention, diagnosis and treatment of infective endocarditis executive summary.Task Force on Infective Endocarditis of the European Society of Cardiology. Eur Heart J 2004; 25:267-76.
44. Fang G, Keys TF, Gentry LO, et al. Prosthetic valve endocarditis resulting from nosocomial bacteremia: a prospective, multicenter study.AnnIntern Med 1993; 119:560-7.
45. Barrau K, Boulamery A, Imbert G, et al. Causative organisms of infective endocarditis according to host status. Clin Microbiol Infect 2004; 10: 302-8.
46. Wyllie DH, Crook DW, Peto TE. Mortality after Staphylococcus aureus bacteraemia in two hospitals in Oxfordshire, 1997-2003: cohort study. BMJ 2006; 333:281.
47. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a metaanalysis. Clin Infect Dis 2003; 36:53-9.
48. Al Nammari SS, Bobak P,Venkatesh R. Methicillin resistant Staphylococcus aureus versus methicillin sensitive Staphylococcus aureus adult haematogenous septic arthritis. Arch Orthop Trauma Surg 2007; 127:537-42.
49. Fowler VG Jr, Kong LK, Corey GR, et al. Recurrent Staphylococcus aureus bacteremia: pulsed-field gel electrophoresis findings in 29 patients. J Infect Dis 1999; 179:1157-61.
50. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990; 34:1227-31.
51. Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with MRSA bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008; 52:3315-20.
52. Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46:193-200.
53. Stryjewski ME, Szczech LA, Benjamin DK Jr, et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 2007; 44:190-6.
54. Hill EE, Peetermans WE, Vanderschueren S, Claus P, Herregods MC, Herijgers P. Methicillin-resistant versus methicillin-sensitive Staphylococcus aureus infective endocarditis. Eur J Clin Microbiol Infect Dis 2008; 27:445-50.
55. Kuo CB, Lin JC, Peng MY, Wang NC, Chang FY. Endocarditis: impact of methicillin-resistant Staphylococcus aureus in hemodialysis patients and community-acquired infection. J Microbiol Immunol Infect 2007; 40: 317-24.
56. Fowler VG Jr, Justice A, Moore C, et al. Risk factors for hematogenous complications of intravascular catheter-associated Staphylococcus aureus bacteremia. Clin Infect Dis 2005; 40:695-703.
57. Wright AJ, Wilson WR. Experimental animal endocarditis. Mayo Clin Proc 1982; 57:10-4.
58. Baddour LM, Christensen GD, Lowrance JH, SimpsonWA. Pathogenesis of experimental endocarditis. Rev Infect Dis 1989; 11:452-63.
59. Hill PC, Wong CG, Voss LM, et al. Prospective study of 125 cases of Staphylococcus aureus bacteremia in children in New Zealand. Pediatr Infect Dis J 2001; 20:868-73.
60. Suryati BA, Watson M. Staphylococcus aureus bacteraemia in children: a 5-year retrospective review. J Paediatr Child Health 2002; 38:290-4.
61. Valente AM, Jain R, Scheurer M, et al. Frequency of infective endocarditis among infants and children with Staphylococcus aureus bacteremia. Pediatrics 2005; 115:e15-9.
62. Abudu L, Blair I, Fraise A, Cheng KK. Methicillin-resistant Staphylococcus aureus (MRSA): a community-based prevalence survey. Epidemiol Infect 2001; 126:351-6.
63. Charlebois ED, Bangsberg DR, Moss NJ, et al. Population-based community prevalence of methicillin-resistant Staphylococcus aureus in the urban poor of San Francisco. Clin Infect Dis 2002; 34:425-33.
64. Jernigan JA, Pullen AL, Partin C, Jarvis WR. Prevalence of and risk factors for colonization with methicillin-resistant Staphylococcus aureus in an outpatient clinic population. Infect Control Hosp Epidemiol 2003; 24: 445-50.
65. von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia: study group. N Engl J Med 2001; 344:11-6.
66. Miró JM, Puig de la Bellacasa J, Gatell JM, et al. Rate of mucosocutaneous carriers of staphylococci in heroin addicts of the Barcelona area and the microbiological characteristics of heroin and the material of injection [in Spanish]. Med Clin (Barc) 1984; 83:620-3.
67. Moreillon P, Que Y, Glauser MP. Staphylococcus aureus (including staphylococcal toxic shock). In: Mandell G, Bennett J, Dolin R, eds. Principles and practice of infectious diseases. Philadelphia: Churchill Livingstone, 2005; 2321-51.
68. Berman DS, Schaefler S, Simberkoff MS, Rahal JJ. Staphylococcus aureus colonization in intravenous drug abusers, dialysis patients, and diabetics. J Infect Dis 1987; 155:829-31.
69. Wulf MW, Sorum M, van Nes A, et al. Prevalence of methicillin-resistant Staphylococcus aureus among veterinarians: an international study. Clin Microbiol Infect 2008; 14:29-34.
70. van Rijen MM, van Keulen PH, Kluytmans JA. Increase in a Dutch hospital of methicillin-resistant Staphylococcus aureus related to animal farming. Clin Infect Dis 2008; 46:261-3.
71. Coello R, Glynn JR, Gaspar C, Picazo JJ, Fereres J. Risk factors for developing clinical infection with methicillin-resistant Staphylococcus aureus (MRSA) amongst hospital patients initially only colonized with MRSA. J Hosp Infect 1997; 37:39-46.
72. Pujol M, Pena C, Pallares R, et al. Nosocomial Staphylococcus aureus bacteremia among nasal carriers of methicillin-resistant and methicillinsusceptible strains. Am J Med 1996; 100:509-16.
73. Huang SS, Hinrichsen V, Stulgis L. Methicillin resistant Staphylococcus infection in the year following detection of carriage [abstract 157]. In: Program and abstracts of the Society of Healthcare Epidemiology of America Annual Meeting (Chicago). Arlington, VA: Society for Healthcare Epidemiology of America, 2006.
74. Datta R, Huang SS. Risk of infection and death due tomethicillin- resistant Staphylococcus aureus in long-term carriers. Clin Infect Dis 2008; 47: 176-81.
75. Buehlmann M, Frei R, Fenner L, Dangel M, Fluckiger U, Widmer AF. Highly effective regimen for decolonization of methicillin-resistant Staphylococcus aureus carriers. Infect Control Hosp Epidemiol 2008; 29:510-6.
76. Fung SK, Louie M, Simor AE. Combined topical and oral antimicrobial therapy for the eradication of methicillin-resistant Staphylococcus aureus (MRSA) colonization in hospitalized patients. Can J Infect Dis 2002; 13: 287-92.
77. Jones JC, Rogers TJ, Brookmeyer P, et al. Mupirocin resistance in patients colonized with methicillin-resistant Staphylococcus aureus in a surgical intensive care unit. Clin Infect Dis 2007; 45:541-7.
78. Simor AE, Phillips E, McGeer A, et al. Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillinresistant Staphylococcus aureus colonization. Clin Infect Dis 2007; 44: 178-85.
79. Coia JE, Duckworth GJ, Edwards DI, et al. Guidelines for the control and prevention of methicillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities. J Hosp Infect 2006; 63(Suppl 1):S1-44.
80. Gould FK, Elliott TS, Foweraker J, et al. Guidelines for the prevention of endocarditis: report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2006; 57: 1035-42.
81. O'Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. MMWR Recomm Rep 2002; 51:1-29.
82. DeJonge M, Burchfield D, Bloom B, et al. Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. J Pediatr 2007; 151:260-5.
83. Fattom AI, Horwith G, Fuller S, Propst M, Naso R. Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials. Vaccine 2004; 22:880-7.
84. Shinefield H, Black S, Fattom A, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002; 346:491-6.
85. ClinicalTrials.gov. Available at: http://www.clinicaltrials.gov. Accessed 17 October 2008.
86. Corey GR. Staphylococcus aureus bloodstream infections: definitions and treatment. Clin Infect Dis 2009; 48(Suppl 4):S254-9 (in this supplement).
87. Mermel LA, Farr BM, Sherertz RJ, et al. Guidelines for the management of intravascular catheter-related infections. J Intraven Nurs 2001; 24: 180-205.
88. Gould IM, MacKenzie FM, Maclennan G, Pacitti D, Watson EJ, Noble DW. Topical antimicrobials in combination with admission screening and barrier precautions to control endemic methicillin-resistant Staphylococcus aureus in an intensive care unit. Int J Antimicrob Agents 2007; 29:536-43.
89. Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. Plast Reconstr Surg 2006; 117:212S-38S.
90. Murray RJ. Staphylococcus aureus infective endocarditis: diagnosis and management guidelines. Intern Med J 2005; 35(Suppl 2):S25-44.
91. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41:1373-406.
92. National Institute for Public Health and the Environment. European Antimicrobial Resistance Surveillance System annual report 2005. The Netherlands, 2006. Available at: http://www.rivm.nl/bibliotheek/rapporten/ 210624001.html. Accessed 9 March 2009.
93. Kim SH, Kim KH, Kim HB, et al. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2008; 52:192-7.
94. Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006; 44:3883-6.
95. Chang S, Sievert DM, Hageman JC, et al. Infection with vancomycinresistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003; 348:1342-7.
96. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38:1673-81.